Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Cancers, Vol. 10, Pages 132: Aptamers: Promising Tools for Cancer Diagnosis and Therapy
Cancers doi: 10.3390/cancers10050132
Authors: Laura Cerchia
The most common approaches to cancer treatment have been, for decades, based on surgical excision, radio- and/or chemotherapy, which, in spite of their modest survival benefits, still encounter several limitations, in part due to their lack of specificity [...]
Cancers, Vol. 10, Pages 131: Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer
Cancers doi: 10.3390/cancers10050131
Authors: Lorenzo Stramucci Angelina Pranteda Gianluca Bossi
TP53 is universally recognized as a pivotal protein in cell-cycle fate and apoptotic induction and, unsurprisingly, it is one of the most commonly hijacked control mechanisms in cancer. Recently, the kinase MKK3 emerged as a potential therapeutic target in different types of solid tumor being linked to mutant p53 gain-of-function. In this review, we summarize the delicate relationship among p53 mutational status, MKK3/MKK6 and the downstream activated master kinase p38MAPK, dissecting a finely-tuned crosstalk, in a potentially cell-context dependent scenario that urges towards a deeper characterization of the different molecular players involved in this signaling cascade and their interactions.
Cancers, Vol. 10, Pages 132: Aptamers: Promising Tools for Cancer Diagnosis and Therapy
Cancers doi: 10.3390/cancers10050132
Authors: Laura Cerchia
The most common approaches to cancer treatment have been, for decades, based on surgical excision, radio- and/or chemotherapy, which, in spite of their modest survival benefits, still encounter several limitations, in part due to their lack of specificity [...]
Cancers, Vol. 10, Pages 131: Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer
Cancers doi: 10.3390/cancers10050131
Authors: Lorenzo Stramucci Angelina Pranteda Gianluca Bossi
TP53 is universally recognized as a pivotal protein in cell-cycle fate and apoptotic induction and, unsurprisingly, it is one of the most commonly hijacked control mechanisms in cancer. Recently, the kinase MKK3 emerged as a potential therapeutic target in different types of solid tumor being linked to mutant p53 gain-of-function. In this review, we summarize the delicate relationship among p53 mutational status, MKK3/MKK6 and the downstream activated master kinase p38MAPK, dissecting a finely-tuned crosstalk, in a potentially cell-context dependent scenario that urges towards a deeper characterization of the different molecular players involved in this signaling cascade and their interactions.
In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and reasoning with the reader (regular type). The authors' commentary follows. A 62-year-old woman with…
https://ift.tt/2HKTUCf
Qian Qin, Veronica B Ajewole, Tiffany G Sheu, Rachel Donohue and Monisha Singh
from Cancer via ola Kala on Inoreader https://ift.tt/2JROIcG
via IFTTT
Pediatric Blood &Cancer, EarlyView.
from Cancer via ola Kala on Inoreader https://ift.tt/2HRN5uR
via IFTTT
